Comprehensive Study Guide for Industrial and Clinical Rheumatology

Clinical Principles of NSAID Prescription and Symptomatic Treatment in Rheumatic Diseases

When prescribing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for patients with rheumatic diseases, specific clinical guidelines must be observed to maximize efficacy and minimize risks. It is a fundamental rule that two NSAIDs should never be prescribed simultaneously. Furthermore, the intravenous administration of a NSAID does not help to avoid gastrointestinal toxicity, as the systemic inhibition of prostaglandins affects the gastric mucosa regardless of the administration route. Special caution is required when a patient is receiving oral anticoagulants, as combining them with NSAIDs can significantly increase the risk of hemorrhage. It is also important to note that an allergy to one specific NSAID class does not automatically exclude the possibility of prescribing an NSAID from another chemical class. The overarching principle for avoiding adverse reactions—most notably upper gastrointestinal tract hemorrhage and gastroduodenal ulcer perforations—is that a NSAID must be prescribed in the minimally efficient dose and for the shortest duration necessary.

In the context of psoriatic arthritis, symptomatic treatment is primarily achieved through the use of NSAIDs. Classes of NSAIDs recommended for these patients include Coxibs and Oxicams. Other treatments, such as antibiotics (Clarithromycin, Benzatinbenzylpenicillin), D-penicillamine, or manual therapy, are not considered standard symptomatic treatments for this condition. Methotrexate is utilized in management but falls under the category of immune suppressive treatment rather than simple symptomatic relief.

Psoriatic Arthritis (PsA): Diagnostic Criteria, Clinical Manifestations, and Management

Psoriatic arthritis is a complex inflammatory disease often associated with the presence of the HLA-B27 marker. A defining clinical feature of this disease is the potential for arthritis mutilans, a severe, destructive form of joint involvement. Diagnosis is formally established using the CASPAR diagnostic criteria. These criteria include clinical evidence of skin psoriasis (personal or family history), nail dystrophy (psoriatic onichodystrophy, which manifests as punctiform erosion or "pitting"), a negative rheumatoid factor (as the disease is typically seronegative), a history of dactylitis (established by a rheumatologist), and characteristic radiological findings. It is important to note that the presence of positive anti-CCP antibodies is not used for the diagnosis of psoriatic arthritis, as it is specific to rheumatoid arthritis.

Radiologically, psoriatic arthritis is characterized by specific signs such as the involvement of distal interphalangeal (DIP) joints and an asymmetrical joint distribution. One of the most distinctive features is the presence of osteolytic lesions in the phalanges and metacarpophalangeal joints, which give the fingers a "telescoped" appearance or a "pencil-in-cup" deformity. Other signs include bone ankylosis, marginal erosions (geodes), and the formation of syndesmophytes. Phalangeal involvement frequently presents as "sausage fingers" (dactylitis) or the aforementioned telescoped fingers. Axial involvement is typically characterized by unilateral or asymmetric sacroiliitis, rather than the symmetric involvement seen in other spondyloarthritides.

Management of the disease involves a multi-faceted approach. Symptomatic treatment is provided by NSAIDs and glucocorticoids. However, immune suppressive treatment, such as Methotrexate, is considered obligatory for controlling disease progression. Biological treatments have also become standard, specifically the use of TNF-α\alpha antagonists (such as Etanercept), monoclonal antibodies, receptor antagonists, and soluble receptors. Before initiating TNF-α\alpha antagonists, screening for latent tuberculosis is mandatory, and these drugs are contraindicated in patients with active or chronic infections like osteomyelitis. Treatment should be temporarily suspended for patients undergoing surgery. Extra-articular complications of PsA include AA amyloidosis (visceral amyloidosis), anterior uveitis, IgA nephropathy, heart failure, and exfoliative dermatitis.

Rheumatoid Arthritis (RA): Pathogenesis, Joint Distribution, and Clinical Markers

Rheumatoid arthritis is a chronic autoimmune disease where the major genetic risk factor is the presence of HLA DR4. The disease is characterized by persistent inflammatory synovitis, which leads to juxtaarticular osteoporosis, marginal erosions, and eventually bone ankylosis. Joint involvement is typically symmetric and polyarticular, involving the proximal interphalangeal (PIP) joints, metacarpophalangeal joints, and the cervical vertebral joints (specifically the atlanto-axial joint). Notably, distal interphalangeal (DIP) joints and the lumbar column are usually spared. Symptoms include morning stiffness and, in acute onsets, systemic features like fever and splenomegaly. Risk factors include female sex (with a female to male ratio of 2.2−2.5:12.2-2.5:1, though this equalizes by age 70) and smoking.

Extra-articular manifestations, caused by lympho-plasmocytic infiltrates or vasculitis, appear in severe cases and are usually associated with high titers of rheumatoid factor (RF). These can include rheumatoid nodules, respiratory tract involvement (most commonly pleurisy), ocular manifestations (iritis, episcleritis, and sicca keratoconjunctivitis), and rheumatoid vasculitis (manifesting as purpura, polyneuropathy, myocardial infarction, or skin ulcers). A severe long-term renal complication is the development of renal amyloidosis.

Diagnosis and assessment rely heavily on proof of autoimmunity, specifically the presence of Rheumatoid Factor (RF) and anti-cyclic-citrullinated-peptide (anti-CCP) antibodies. RF can belong to any class of immunoglobulins; while it can be found in low titers in healthy individuals or those with viral hepatitis, high titers in RA signify a higher risk of systemic manifestations. Radiographic progression in RA is characterized by microvascular lesions, juxtaarticular osteoporosis, and a local increase in synovial cells and hypervascularization.

Therapeutic Management of Rheumatoid Arthritis

The "gold standard" for non-biologic Disease-Modifying Anti-Rheumatic Drug (DMARD) treatment in rheumatoid arthritis is Methotrexate. It is administered once a week (orally, intramuscularly, or subcutaneously) and requires periodic hepatic enzyme control to monitor for toxicity. Methotrexate and Leflunomide are recognized for their ability to slow down the progression of joint involvement as evidenced by X-ray data. NSAIDs are used for symptomatic relief, with gastro-intestinal tract damage being their most common side effect. Glucocorticoids are also used to manage inflammation. Interestingly, paracetamol may decrease the level of rheumatoid factor. For severe or refractory cases, biological treatments may be utilized.

Reactive Arthritis (ReA): Etiology and Clinical Features

Reactive arthritis is part of the seronegative spondyloarthritis group and is strongly associated with the HLA-B27 genetic marker (present in 50−75%50-75\% of patients). It is an asymmetric oligoarthritis that most frequently affects the sacroiliac joint and the joints of the lower extremities. The condition is often triggered by enteric infections—specifically species such as Shigella flexneri, Salmonella, and Yersinia—or urogenital infections like Chlamydia and Ureaplasma urealyticum. Clinical manifestations often include "sausage-like" digits, enthesitis (inflammatory lesions that may lead to ossification), and muco-cutaneous involvement such as circinate balanitis, nail dystrophy, and oral ulcers.

Extra-articular manifestations are common, with acute anterior uveitis being the most frequent. Other manifestations include aortic valve insufficiency, IgA nephropathy, renal amyloidosis, and, rarely, diffuse pulmonary fibrosis. Physical examination may employ the Schöber test, which is a method used to assess the mobility of the lumbar column. Laboratory findings typically include elevated ESR, increased C-reactive protein, and mild normochromic, normocytic anemia. Synovial fluid analysis shows features of specific inflammation with a predominance of lymphocytes.

Treatment of reactive arthritis involves etiological therapy with antibiotics. For persistent cases, Sulfasalazine (up to 3 g/day3\,g/day in divided doses) can be beneficial. While systemic glucocorticoids are not routinely used for the joint disease itself, they are critical for treating uveitis, and intralesional injections can be used for tendinitis. Poor life prognosis is associated with complications like renal amyloidosis and aortic insufficiency.

Acute Rheumatic Fever (ARF): Criteria and Clinical Timeline

Acute Rheumatic Fever is an autoimmune response following a Group A hemolytic streptococcus infection. The specific morphological abnormality is the Aschoff nodule. The disease primarily affects children and adolescents aged 7−15 years7-15\,years. There is a characteristic latent period of 2−4 weeks2-4\,weeks between the initial streptococcal infection and the onset of rheumatic symptoms. The pathogenic properties of the streptococcus are linked to Protein M on its membrane and the release of enzymes such as streptokinase and streptohialuronidase. Laboratory certification of the streptococcal etiology is provided by measuring Antistreptolysin-O (ASLO) and antistreptokinase titers. The most sensitive index for evaluating disease activity is the Erythrocyte Sedimentation Rate (ESR).

Clinical manifestations include migratory polyarthritis and carditis. Arthritis in ARF has a maximal duration of 2−3 weeks2-3\,weeks. Regarding cardiac involvement, mitral insufficiency typically develops within 2−3 weeks2-3\,weeks, while rheumatic mitral stenosis takes a much longer period of more than 6 months6\,months to develop. Sydenham chorea is another manifestation, affecting predominantly girls aged 6−156-15. ECG findings often include an increase of the P-R interval to greater than 0.20 seconds0.20\,seconds, along with rhythm and conduction disorders. Echocardiographic signs of endocarditis include marginal valve thickening, regurgitation, and valve hypokinesia.

Treatment of ARF involves antibacterial drugs, with Penicillins (such as Fenoximethylpeniciline for 10 days10\,days or Benzatin benzilpeniciline) being the first line. For patients with penicillin allergies, macrolides like Azithromycin (5−6 days5-6\,days) or Clarithromycin (14 days14\,days) are used. Anti-inflammatory treatment includes NSAIDs (indicated for arthritis or minimal carditis) and corticosteroids (for severe pancarditis or heart failure). Symptomatic treatment for chorea involves anticonvulsants like Carbamazepine or Phenobarbital.

Gout: Metabolic Mechanisms and Clinical Diagnosis

Gout is a metabolic disease characterized by hyperuricemia and the deposition of uric acid crystals in synovial fluid and tissues. Risk factors include male gender, genetic defects in purine metabolism, diets high in purines, ethanol abuse, and certain drugs like diuretics. Hyperuricemia is defined by serum uric acid values exceeding 0.36−0.49 mmol/L0.36-0.49\,mmol/L in men and 0.30−0.39 mmol/L0.30-0.39\,mmol/L in women, or urinary uric acid excretion exceeding 900 mg/24 hours900\,mg/24\,hours. The joint most frequently affected is the first metatarsophalangeal joint. The mechanism of a gout flare involves the penetration of urates into the synovial fluid, which triggers inflammation.

Chronic gout can lead to characteristic hand deformities known as "pseudorheumatoid hand" and the formation of tophi (nodules containing uric acid crystals). Common locations for tophi include the ears, elbows, and the olecranon bursa. Radiographically, gout is identified by "punched-out" bone erosions and marginal sclerosis. Systemic involvement includes nephrolithiasis, interstitial nephritis, and atherosclerosis, which are associated with a poor prognosis. Neurological symptoms such as carpal tunnel syndrome or paraparesis may occur if tophi form in the extradural space.

Acute flares are treated with NSAIDs, Colchicine, and Methylprednisolone. For chronic management, uric acid depressive treatments include Allopurinol and Febuxostat. Uricolytic treatment may involve Uricase or Razburicase. Allopurinol therapy must be monitored for side effects such as dyspepsia, thrombocytopenia, and leukopenia.

Systemic Lupus Erythematosus (SLE): Multi-System Clinical Profile

SLE is a systemic autoimmune disease characterized by a wide range of clinical manifestations. Hematologically, patients often exhibit leukopenia, thrombocytopenia, and hemolytic anemia, along with an increased ESR. The most characteristic skin manifestation is the butterfly-shaped malar rash, though discoid rashes and livedo reticularis also occur. Cardiac involvement is frequent, with pericarditis being the most common, alongside Libman-Sacks endocarditis (most frequently affecting the mitral valve, leading to mitral insufficiency). Myocarditis can present as tachycardia, extrasystolia, and heart failure. Renal involvement, or lupus nephritis, is a major prognostic factor; diffuse sclerotic lupus nephritis (where over 90%90\% of glomeruli are sclerotic) carries the worst prognosis.

Nervous system involvement most frequently manifests as depression, but can also include psychosis, convulsions, and cognitive dysfunction. Antiphospholipid syndrome, characterized by recurrent spontaneous abortions, arterial/venous thromboses, and increased anticardiolipin antibodies, often coexists with SLE. Immunological markers for SLE include increased titers of ANA, anti-dsDNA (frequently associated with nephritis), and anti-Sm antibodies. Anti-SSA (Ro) antibodies are associated with neonatal lupus and Sjögren syndrome.

Treatment involves corticosteroids, which are the most efficient drugs for general management, and Cyclophosphamide for severe disease. Hydroxychloroquine is considered the least toxic option. Maintenance of remission often involves low-dose Prednisolone (10−15 mg/day10-15\,mg/day) and Methotrexate (5.0−7.5 mg/week5.0-7.5\,mg/week). Pregnancy in SLE patients is associated with an increased risk of spontaneous abortion, and while High-dose corticosteroids can be used to treat hemolytic anemia or severe flares, they must be managed carefully due to potential fetal effects and complications like pulse-therapy induced hypertension or seizures.

Systemic Sclerosis, Mixed Connective Tissue Disease, and Sjögren Syndrome

Systemic Sclerosis (Scleroderma) is diagnosed using criteria that include skin thickening of the fingers (sclerodactily), Raynaud's syndrome, digital tip ulcers, and interstitial lung disease. Dysphagia is a symptom but not an ACR/EULAR criterion. Renal crisis in systemic sclerosis manifests as malignant arterial hypertension. Radiological findings include soft tissue calcinosis and distal phalangeal osteolysis. Autoantibodies such as anti-topoisomerase (Scl-70) and anti-centromere are characteristic. Lung involvement is marked by diffuse interstitial fibrosis (honeycomb lung) and restrictive syndrome on functional tests.

Mixed Connective Tissue Disease (MCTD) is defined by the presence of anti-U1RNP antibodies, which are generally associated with a relatively good prognosis for organ involvement. Clinical features include Raynaud's phenomenon, synovitis, sclerodactily, and a photosensitive rash. Treatment utilizes NSAIDs, corticosteroids, and cytostatic immunosuppressors.

Sjögren Syndrome is characterized by xerophthalmia (dry eyes) and xerostomia (dry mouth) due to the involvement of the lacrimal and salivary glands. A biopsy of minor salivary glands typically shows focal lymphocytic infiltrate. Skin involvement may include palpable purpura. Laboratory markers often show positive rheumatoid factor and antinuclear antibodies. Treatment focuses on local relief, such as artificial tears and artificial saliva.

Osteoarthritis (OA): Pathophysiology and Staging

Osteoarthritis is a degenerative joint disease driven by proteolytic systems produced by chondrocytes called metalloproteinases. Clinical hallmarks include Heberden nodules (at the distal interphalangeal joints) and Bouchard nodules (at the proximal interphalangeal joints). Morning stiffness in OA is brief, typically lasting only 5−30 minutes5-30\,minutes. Radiographic staging follows the Kellgren-Lawrence system: Stage I shows minimal changes with few osteophytes; Stage III involves advanced changes with a practically absent joint space and massive osteophytes. Primary hip OA often has a hereditary aspect, while secondary hip OA is usually unilateral and results from trauma.

Treatment includes "rapid acting" symptomatic drugs like NSAIDs and analgesics, and "slow-acting" symptomatic drugs (SYSADOA) like Glucosamine and Chondroitin-sulphate. Viscosupplementation is achieved through the intra-articular injection of hyaluronic acid. Kinetotherapy is essential for preventing muscle atrophy and maintaining joint stability.

Osteoporosis: Diagnostic T-Scores and Fracture Management

Osteoporosis is defined by a T-score of −2.5 SD-2.5\,SD or lower on Dual-energy X-ray Absorptiometry (DXA). A T-score between −1.0-1.0 and −2.5 SD-2.5\,SD is classified as osteopenia. The Z-score compares bone mineral density to subjects of the same age and sex. Major osteoporotic fractures typically occur in the proximal third of the femur, the vertebral column, and the distal radius. Fracture risk for the next 10 years is assessed using the FRAX tool. Clinical signs include height reduction, worsening thoracic kyphosis, and fragility fractures. Vitamin D supplementation of 800 IU800\,IU daily is recommended for those over 50.

Pharmacological treatment includes bisphosphonates (Alendronate, Zolendronate, Ibandronate) and Denosumab, a biological agent that acts as a RANKL inhibitor. Bone resorption markers include collagen type I telopeptides, hydroxyproline, and 5p tartrate-resistant acid phosphatase. Secondary osteoporosis can be caused by rheumatoid arthritis, type I diabetes, and long-term corticosteroid use.

Systemic Vasculitis: Classification and Etiology

Vasculitides are classified by the size of the affected vessels. Large-size vessel vasculitis includes Takayasu arteritis and Giant Cell Arteritis, often manifesting with pulse deficits and pathological murmurs. Polyarteritis nodosa (PAN) affects medium-sized vessels and is frequently associated with HBV infection; its pathognomonic sign is subcutaneous nodules. Small-size vessel vasculitis includes Granulomatosis with polyangiitis (Wegener) and IgA vasculitis (Henoch-Schönlein).

ANCA-associated vasculitides include Granulomatosis with polyangiitis (associated with c-ANCA/Proteinase 3), Microscopic polyangiitis (associated with p-ANCA/Myeloperoxidase), and Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), the latter often preceded by bronchial asthma and allergic rhinitis. IgA vasculitis is characterized by IgA deposits in small vessels and circulating immune complexes, manifesting with palpable purpura and gastrointestinal or renal involvement. Treatment for severe vasculitis like Wegener’s typically involves high-dose corticosteroids combined with Cyclophosphamide or Rituximab.